Didn't find what you were looking for?

Discover the latest press releases, media coverage, and important announcements from Actorius Innovations and Research and see how we're making headlines in the industry. News & Press Updates News, Media & Announcements Latest press releases, media coverage, and important announcements from Actorius Innovations and Research. Read More March 17, 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More March 17, 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More March 17, 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More March 14, 2026 Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More February 5, 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More April 11, 2024 Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Read More March 6, 2023 Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Read More August 9, 2022 Revolutionary OncoDiscover® Blood Test for Early Cancer Detection - Metro News Gujarat Dr. Jayant Khandare interview with Metro News Gujarat Read More April 23, 2020 Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read More August 24, 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More August 24, 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More August 24, 2019 Startup Mantra: Making cancer detection more accessible and affordable to people Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume... First Prev 1 Page 1 Next Last

PD-L1 on CTCs enables monitoring, recurrence tracking, and minimal residual disease. Publications June 3, 2025 Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. Background The role of circulating tumor cells (CTCs) has been well established in predicting survival in metastatic settings, particularly in breast, colorectal, and prostate cancers. However, their clinical utility has been limited due to high costs, variability in sensitivity and accuracy, and the use of cutoff-based interpretations. The biological significance of CTCs—from extravasation and invasion to their contribution to tumor microenvironment dynamics and tumor burden—suggests greater clinical relevance than is currently applied in practice. Their role in monitoring minimal cellular residual disease (MCRD), especially in early-stage cancers post-surgery, remains underexplored, including decisions regarding therapy duration in diseases such as colorectal cancer and longitudinal monitoring for recurrence. Dynamic PD-L1 expression on CTCs may indicate incomplete tumor resection or treatment response and may also reflect cellular dormancy in circulation, potentially enabling immune evasion. In this study, we report the expression of PD-L1 on CTCs and CTC clusters in colorectal cancer patients. Methods We retrospectively analyzed 666 colorectal cancer patients (63.06% male and 36.94% female), spanning early- to late-stage disease, for the presence of CTCs with and without PD-L1 expression, as well as CTC clusters. CTCs were detected using the CDSCO-approved OncoDiscover platform in 1.5 mL of peripheral blood. Cells were classified as CTCs if they were EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻, and were identified using an automated Zeiss microscope system. Results At baseline analysis, 74.25% (n = 591) of patients had ≥1 CTC per 1.5 mL of blood. CTC counts ranged from 1 to 20 cells. Among patients with detectable CTCs, 74.62% (n = 441) exhibited PD-L1 expression. The highest proportion of CTCs (~25.86%, n = 352) was observed in the 61–70 years age group. CTC clusters were detected in 13.00% (n = 156) of patients, and notably, more clusters were observed during follow-up compared with baseline. The mean CTC count (including clusters) was 1.71, while the mean PD-L1–positive CTC count was 1.02. Conclusions PD-L1 expression on CTCs may contribute to their ability to persist in circulation through immune evasion, potentially enabling dormancy via surface protein overexpression that helps them avoid elimination by immune T cells. The CTC–PD-L1 assay shows strong potential for patient surveillance both before and after treatment in assessing minimal cellular residual disease. Further clinical studies in this direction are strongly warranted. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover enables early cancer spread detection and faster diagnosis. | BS Article Press Release August 24, 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… A team of Pune scientists have discovered a technology that can detect within mere hours, the spread of cancer and claim that the new finding reduces considerably the time taken for detecting the disease. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process. Presently, in India, the final diagnosis report to detect the spread of cancer takes about 12 days whereas, with OncoDiscover technology, doctors can detect it in a mere 3.5 hours. Dr Khandare told ANI, "We felt the need for this technology because global cancer is spreading. 90 per cent of the people get to know they have cancer when it is at the second stage but through this technology, we can try saving that 90 per cent. This technology is needed to detect cancer at an early stage." View full article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 profiling supports therapy stratification and monitoring in cancers. Publications September 16, 2025 PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. Abstract Background Overexpression of the dynamic protein PD-L1 on circulating tumor cells (CTCs) is a highly implicative biomarker that represents post–curative intent status, minimal residual disease (MRD), disease aggressiveness, therapeutic response, and metastatic progression. We evaluated the correlation among CTC detection, PD-L1 expression, and CTC clusters present in solid tumors, namely lung, breast, colorectal, ovarian, and prostate carcinomas. Longitudinal monitoring of CTCs remains a major focus after treatments, including surgical intervention with curative intent. Methods Retrospectively, we analyzed 328 cancer patients (male 163, female 165) across stages, consisting of a total of 383 samples with baseline and follow-ups (n = 55). Cancer types included lung (27.13%), colorectal cancer (21.95%), breast (9.75%), ovary (4.2%), prostate (3.9%), and others. CTCs and clusters were detected from 1.5 ml peripheral blood using the OncoDiscover platform approved by the Central Drugs Standard Control Organization of India. The platform contains a multifunctional magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibody. CTCs were confirmed as EpCAM+ve, CK18+ve, DAPI+ve, and CD45–ve. PD-L1 expression on CTCs was detected based on the linear intensity gradients of fluorescence signals using image acquisition on an automated fluorescence microscope. Results Among the 383 samples with baseline and follow-ups, 69.45% of patients had CTCs ranging from 1–11. Approximately 77% of patients were above the age of 50. The total number of CTCs observed was ~649 with a mean distribution of ~1.69. CTCs with PD-L1 overexpression were observed in 55.35% of patients (n = 266). Higher CTC prevalence was observed in lung cancer (24.75%), followed by colorectal cancer (21.57%) and breast cancer (5.89%). CTC clusters were observed in 10.18% of patient samples. Notably, concurrent positivity for both CTCs and PD-L1 expression was most prevalent in lung cancer patients, suggesting a potential aggressive disease phenotype and therapeutic vulnerability. Conclusions The findings support the integrated use of CTCs and their PD-L1 expression as a composite biomarker strategy to stratify patients for targeted therapies, immunotherapeutic interventions, and longitudinal monitoring. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Publications April 4, 2024 Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Background The lack of appropriate prognostic biomarkers remains a significant obstacle in the early detection of Head and Neck Squamous Cell Carcinoma (HNSCC), a cancer type with a high mortality rate. Despite considerable advancements in treatment, the success in diagnosing HNSCC at an early stage still needs to be improved. Nuclear factor erythroid 2-related factor 2 (Nrf2) and Sonic Hedgehog (Shh) are overexpressed in various cancers, including HNSCC, and have recently been proposed as possible therapeutic targets for HNSCC. Circulating Tumor Cell (CTC) is a novel concept used for the early detection of cancers, and studies have suggested that a higher CTC count is associated with the aggressiveness of HNSCC and poor survival rates. Therefore, we aimed to establish molecular markers for the early diagnosis of HNSCC considering Shh/Nrf2 overexpression in the background. In addition, the relation between Shh/Nrf2 and CTCs is still unexplored in HNSCC patients. Methods In the present study, we selected a cohort of 151 HNSCC patients and categorized them as CTC positive or negative based on the presence or absence of CTCs in their peripheral blood. Data on demographic and clinicopathological features with the survival of the patients were analyzed to select the patient cohort to study Shh/Nrf2 expression. Shh and Nrf2 expression was measured by qRT-PCR. Results Considering significant demographic [smoking, betel leaf (p-value < 0.0001)] and clinicopathological risk factors [RBC count (p < 0.05), Platelet count (p < 0.05), Neutrophil count (p < 0.005), MCV (p < 0.0001), NLR (p < 0.05), MLR (p < 0.05)], patients who tested positive for CTC also exhibited significant overexpression of Shh/Nrf2 in both blood and tissue compared to CTC-negative patients. A strong association exists between CTCs and tumor grade. Following chemotherapy (a combination of Cisplatin, 5FU, and Paclitaxel), the frequency of CTCs was significantly decreased in patients with HNSCC who had tested positive for CTCs. The Kaplan–Meier plot illustrated that a higher number of CTCs is associated with poorer overall survival (OS) in patients with HNSCC. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Innovations AACR 2026 Publications Publications March 17, 2026 AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Abstract Background While 90% of cancer deaths are associated with metastasis, it is imperative to monitor early-stage cancer patients for the presence of systemic disease to improve overall survival (OS) and progression-free survival (PFS). Despite complete remission, up to 25–50% of colorectal cancer (CRC) stage II–III and early breast cancer cases are known to relapse. Furthermore, the existence of microtumors often remains undetected by radio-imaging tools due to their limited detection thresholds. Following curative-intent therapies, minimal residual cellular disease (MRCD) may persist and is often represented by circulating tumour cells (CTCs). These cells are known for their ability to extravasate and invade distant sites from the primary tumor. They can also evade immune surveillance. Therefore, there is a need to design safer extracorporeal devices for the capture and depletion of CTCs, particularly those overexpressing PD-L1. In this study, we designed an automated device to capture and remove CTCs from whole blood. Methods We developed an automated microprocessor-operated fluidic device, OncoMetastat, equipped with cartridges for blood and reagent tubes, along with a 3D-printed biocompatible spiral channel. The controller unit powers peristaltic pumps that circulate blood through the spiral channel (96 mm diameter × 6 mm height). The system incorporates 2 mm glass beads conjugated with antibodies and transferrin. Additionally, four vibrators provide micro-stirring to enhance CTC capture from 5–10 mL of patient blood samples (n = 54). White blood cell (WBC) count, hemolysis, and protein binding were measured. The beads were scanned for CTCs using markers CK18⁺, DAPI⁺, and CD45⁻ through an automated imaging system and compared with the OncoDiscover CTC enumeration platform approved by CDSCO India. We analyzed true positives, false negatives, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Results Retrospectively, blood samples from 54 pan-cancer patients—including breast, colorectal, prostate, and lung cancer—were analyzed to capture and deplete CTCs. The OncoMetastat platform demonstrated a capture efficiency of over 90% when compared with the OncoDiscover platform. Automated scanning achieved 100% efficiency in CTC imaging compared with manual imaging. Leukocyte adhesion was low with anti-EpCAM and transferrin-coated glass beads (2 ± 1 WBCs per sample, n = 54). WBC counts showed cancer-type-specific trends (mean WBC count/mL: 4.9 × 10⁶ for breast cancer, 3.9 × 10⁶ for rectal cancer, and 3.5 × 10⁶ for prostate cancer), representing a 40% decrease compared with healthy controls (mean 6.9 × 10⁶ WBCs/mL). Clinically insignificant hemolysis (<1%) and minimal protein binding (~1.5%) were observed. Vibration-assisted operation enhanced CTC sequestration, achieving more than 90% cell capture efficiency. The platform demonstrated sensitivity of 94.4%, specificity of 92.9%, PPV of 94.4%, NPV of 92.9%, and overall accuracy of 93.8% for CTC capture. Conclusion This study demonstrates efficient and specific depletion of CTCs using the automated device. The platform shows potential as an extracorporeal system capable of removing CTCs from whole blood, thereby offering a promising strategy to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers Publications March 17, 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Abstract Background Urological cancers, including prostate, bladder, kidney, testicular, and penile cancers, often fail to show symptoms or show only nonspecific symptoms at early stages. This leads to delayed diagnosis, treatment decisions, and outcomes. Circulating tumor cells (CTCs) predict the outcome in metastatic prostate cancer (PC). Furthermore, in bladder cancer, CTC positivity is linked to muscle invasion, higher recurrence risk, and worse clinical outcomes. CTC PD-L1 expression could evade immune elimination. In spite of complete remission, a higher percentage of patients are known to recur in urothelial cancers. CTCs acting as minimal cellular residual disease (MCRD) are highly implicated, knowing their capacity to be dormant systemically with extravasation and invasion to distant organs. We analyzed the presence of CTCs with PD-L1 over-expression in urological cancers at baseline and follow-ups. Methods Retrospectively, a total of 359 urological cancer patients were evaluated for CTC positivity, including 307 at baseline and 52 follow-up samples. The cancer type distribution was prostate cancer (n = 139), bladder (n = 188), kidney (n = 10), testes (n = 2), penis (n = 8), urothelial (n = 12), etc. Ninety-five percent of the patients were male (n = 293) and 5% were female (n = 14), with most patients aged 61 to 80 years. CTCs expressing PD-L1, positive CTCs, and CTC clusters were analyzed using OncoDiscover® PD-L1 markers and a Zeiss fluorescence automated microscope. Demographics, cancer mean distribution, and CTC and cluster frequency were analyzed. Results Of the 359 patients, CTCs were detected in 68.2% (245/359) of patients, while PD-L1 over-expression on CTCs was present in 49.9% (179/359) of patients. However, CTC clusters were uncommon and occurred in 7.2% (26/359) of patients. Across cancer types (total CTCs = 436), prostate cancer accounted for higher CTCs with a mean CTC distribution of 2.18, while bladder was 0.74, urothelial 0.34, testes 0.18, kidney 0.74, and penis 0.38, respectively. CTC PD-L1 was highest in prostate cancer (46.1%) compared to other cancers, and CTC cluster prevalence was 1.8% in prostate cancer, urothelial (0.9%), and bladder (0.2%) cancers. In CTC-positive cases, 56.3% of patients had only one CTC, 27.8% showed two CTCs, and 8.2% had three. The mean across all patients was 0.6 for CTCs, 0.3 for CTC-PD-L1 positive, and 0.1 for clusters. Conclusions CTCs with PD-L1-positive overexpression were observed across urological cancers, being particularly higher in prostate cancer compared to bladder, kidney, and penis cancers. Many patients are known to recur in spite of complete remission, possibly due to the presence of aggressive CTCs in circulation that could evade the immune system. More studies assessing the presence of CTCs with PD-L1 expression are justified in urological cancers for minimal cellular residual disease and as prognostication. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations | ANI News Press Release March 17, 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Click the button below to read the full story Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Polymer-based drug delivery for targeted GI tract release (stomach, intestine, colon). Patents February 26, 2020 Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Patent Details Related patent documents CA3060026 EP3612196 WO/2018/193337 US20200129442 US20230181479 Granted US and Indian Patent Actorius Innovations and Research View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

PD-L1 on CTCs and ctDNA enables real-time monitoring of breast cancer progression. Publications June 3, 2025 PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. Background Tumor-derived components, such as dual biomarkers including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), provide comprehensive real-time insights into the tumor microenvironment. Minimal cellular residual disease (MCRD), dynamic cell surface protein overexpression, residual tumor burden after curative-intent resection, and decisions regarding adjunct therapy or therapy de-escalation are critical aspects of patient management. Similar to the PD-L1 combined positive score (CPS) in tissue samples, PD-L1 expression on CTCs represents a promising dynamic biomarker, particularly in the context of epithelial-to-mesenchymal transition (EMT). EMT may contribute to immune evasion by deactivating T cells, thereby facilitating micro-metastatic progression, which remains challenging to detect and manage. In this study, we report PD-L1 expression as a dynamic biomarker on circulating tumor cells across early- to late-stage breast cancer patients. Methods In this retrospective analysis, peripheral blood samples from 1,294 breast cancer patients were evaluated for the presence of CTCs, PD-L1 expression on CTCs, and CTC clusters. CTCs were enumerated using the OncoDiscover platform, approved by CDSCO-India, from 1.5 mL of peripheral blood. The system consists of a multi-component magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibodies. CTCs were identified based on EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ markers. PD-L1 expression on CTCs was quantified using linear intensity gradients of fluorescence signals acquired through an automated Zeiss microscope. Additionally, a computational model was developed to evaluate mean CTC distribution, perform regression analysis, and assess CTC predictability. Results CTC counts ranged from 1 to 20 per 1.5 mL of blood. At baseline analysis, 73.20% (n = 978) of patients had ≥1 CTC. Among patients with detectable CTCs, 87.69% (n = 406 of 463) exhibited PD-L1 expression. The highest proportion of total CTCs (~21.61%, n = 1,125) was observed in the 41–50-year age group. The highest frequency of CTC clusters (~29.08%, n = 41) and PD-L1–positive CTCs (~42.91%, n = 324) was observed in the 51–60-year age group. CTC clusters were detected in 2.71% (n = 141) of total patients. The mean CTC count (including clusters) was 3.90, while the mean PD-L1–positive CTC count was 3.40. The computational model demonstrated a correlation between blood-based outcomes and normal probability scores. Conclusions The observed inter-patient heterogeneity suggests potential biological and pharmacodynamic relevance of both CTCs and PD-L1 expression. Larger clinical studies are warranted to further evaluate PD-L1 expression on CTCs, particularly in early-stage cancers. Patients with minimal cellular residual disease, despite the absence of radiographic evidence, may represent a higher-risk group for metastasis progression and may benefit from enhanced stratification strategies. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Combined ctDNA and CTC analysis improves MRD detection and cancer progression monitoring. Publications June 3, 2024 ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. Background: Post curative-intent surgery and therapy, the presence of circulating tumor DNA (ctDNA) load represents minimal residual disease (MRD). Conversely, the presence of circulating tumor cells (CTCs) in stage I–II cancer or even in disease-free survival (DFS) patients indicates occult cellular residual disease (CRD) with undetectable micrometastasis. These complementary biomarkers in patients undergoing treatment act as indicators of non-responsiveness, suggesting the need for treatment modifications. Methods: Retrospectively, we monitored a cohort of 46 cancer patients for MRD using ctDNA and CTCs who were treated or undergoing treatment (e.g., lung, breast, colon, and head and neck cancer; n = 14, 7, 6, and 4, respectively). The OncoMonitor test detected single nucleotide variations (SNVs), small insertions and deletions (INDELs), copy number variations (CNVs), and translocations (fusions). Libraries were prepared using a hybridization-capture method covering 1000 targets with a mean sequencing depth of 5000× on the Illumina NextSeq 2000 in paired-end mode (150 × 2). Variant calling was performed using a proprietary bioinformatics pipeline, iCare. CTCs were isolated using the OncoDiscover platform, which possesses an anti-EpCAM antibody-based immunomagnetic system per 1.5 mL of blood. CTCs were confirmed using CK18+, PD-L1, and CD45 markers with a motorized fluorescence microscope. Results: From ctDNA analysis, 47.82% (n = 22) of patients were identified with at least one actionable genomic finding. Among these, 13.04% (n = 6) of patients showed EGFR driver mutations. Additionally, 19.56% (n = 9) of patients were identified with either EGFR driver, KRAS, or PI3K passenger mutations, while 4.34% (n = 2) were identified with ALK–EML4 fusion. The average ctDNA load obtained in patients with progressive disease (n = 26) was 8.2 molecules per 1 mL of plasma. At least one CTC was detected in 61.53% (n = 16) of progressive disease patients, with the highest count of four CTCs identified in 7.69% (n = 2) of patients. Only 30% (n = 6) of patients with stable disease were identified with at least one genomic finding from a total of 20 patients upon ctDNA analysis, with an average ctDNA load of 2.2 molecules per 1 mL of plasma. Patients with clinically progressive disease showed ctDNA load approximately fourfold higher than those with stable disease during treatment. No patients with stable disease were identified with four CTCs, as opposed to 7.69% in the progressive disease cohort during treatment. Conclusions: We observed that ctDNA and CTCs complement MRD status even after curative-intent surgery and therapy, with the potential to identify patients likely to experience disease progression. Our findings strongly indicate a positive correlation between ctDNA load, the number of detected CTCs, and disease progression based on radiological findings. These biomarkers can support practical clinical decision-making. Further studies are necessary to validate these findings and improve follow-up strategies for better clinical outcomes. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Patents February 13, 2023 Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. The present disclosure relates to non-hemolytic blood compatible devices and methods for capture, enumeration, removal of disease-causing agents from the blood and for the treatment of the cancer patients. The said devices incorporating non-hemolytic compositions are useful for removing disease-causing agents 'ex vivo' from cancer patient's blood to prevent/delay the proliferation of cancer. The devices retain disease-causing agents in particular Circulating Tumor Cells (CTCs), allowing the passage of other blood constituents retaining the viability of hematopoietic cells. Related patent documents WO/2023/229674 CA3255372 IN202527040253 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe